Rossari Biotech Navigates Q3 FY26 with Strategic Growth and Margin Focus

Rossari Biotech Limited, a prominent specialty chemicals manufacturer, has reported a resilient performance for Q3 FY26, demonstrating healthy year-on-year growth despite a softer domestic demand environment. The company's consolidated revenues grew by 13% YoY to Rs. 581.7 crore, supported by a balanced contribution across its diverse business segments and continued traction in international operations. Consolidated EBITDA stood at Rs. 68.9 crore, with an EBITDA margin of 11.8%. Profitability during the quarter was impacted by ongoing investments in capacity expansion, new product development, market-seeding initiatives, and higher employee-related costs following the implementation of new labor codes. Despite these headwinds, the company's diversified business model and strong customer relationships enabled it to sustain growth momentum.

Segment-wise, the Home, Personal Care and Performance Chemicals (HPPC) segment recorded an 11% YoY growth, reflecting stable demand amidst a muted domestic environment. The Textile Specialty Chemicals (TSC) segment delivered a healthy 18% YoY growth, while the Animal Health and Nutrition (AHN) business reported a strong 39% YoY growth, driven by improved traction across key end-user markets. This broad-based segmental performance underpinned the overall growth during the quarter. However, the Institutional and B2C segments remained subdued, though operational losses sequentially reduced, indicating progress in cost and portfolio rationalization efforts. Excluding these segments, the core B2B operations delivered an EBITDA of Rs. 72 crore with a margin of approximately 14%, reflecting disciplined cost management.

Strategic Initiatives and Future Outlook

Rossari Biotech is actively pursuing several strategic initiatives to bolster its long-term growth trajectory. A significant development is the Board's in-principle approval for setting up greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA) under Rossari International Limited, its wholly-owned subsidiary. This project aims to enhance supply chain resilience, improve speed-to-market, and support the company's international growth strategy by leveraging KSA's strategic proximity to key export markets and raw material availability. The funding for this project is expected to be a prudent mix of equity, debt, and internal accruals.

On the manufacturing front, the newly commissioned 15,000 MTPA Ethoxylation facility at Unitop is undergoing a steady ramp-up, with optimal utilization expected to take at least two years, reaching full capacity by 2027. The company is also managing near-term constraints in Ethylene Oxide availability by prudently managing supplies and leveraging the fungibility of its reactors for non-Ethylene Oxide product lines. Additionally, a small formulation facility in Thailand and a new premix plant for the AHN business are expected to come onstream by the end of Q4 FY26 or early Q1 FY27, further supporting export-led growth and AHN volumes.

Management's Perspective and Key Takeaways

Management emphasized its focus on improving capacity utilization, strengthening its product portfolio, and maintaining financial discipline. While near-term investments and strategic initiatives have led to a moderation in ROCE and ROE, the balance sheet remains strong with healthy liquidity and conservative leverage. The company is confident of improved return metrics as these investments begin to yield results. The working capital position also improved sequentially in Q3 due to better collections, moving back towards normalized levels. The company is also actively re-evaluating its non-profitable B2C products and considering selling parts of its consumer businesses to enhance profitability.

Looking ahead, Rossari Biotech remains focused on disciplined execution, customer-led innovation, and sustainable value creation. Supported by strong R&D capabilities and expanding capacities, the company is well-positioned to navigate near-term volatility and deliver consistent, profitable growth for all stakeholders. The strategic move into KSA, coupled with domestic capacity expansions and new product developments, underscores a clear vision for global leadership in specialty chemicals.